SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as community members rally around the revival of OG memes and the unique culture surrounding Rage Comics. Discussions focus on the community's dedication, consistent activity, and the potential for significant growth. Believers are eagerly anticipating a return to the 2021 vibes and a renewed focus on long-term conviction in the memecoin space.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users draw parallels to Bitcoin and emphasize the project's long-term vision within the cannabis culture. The community highlights the coin's cultural relevance and consistent building, especially with discussions around potential cannabis reform and its impact on the industry. Some users are comparing Weedcoin to established cannabis stocks such as $TLRY.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Despite a reported earnings beat and positive guidance, Broadcom ($AVGO) is trending down, sparking discussion around profit-taking and concerns about AI revenue margins. Community members are debating whether this is a buying opportunity or a sign of an overvalued stock due for a correction, drawing comparisons to recent market reactions to other tech earnings. Some traders point to analyst target raises as a bullish signal, while others express skepticism about the long-term sustainability of AI-driven growth.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that the U.S. government may loosen federal restrictions on marijuana, potentially reclassifying it as a Schedule III drug. The community is actively discussing the potential implications of this policy change, particularly regarding the company's future growth and possible short squeeze scenarios. Some investors believe TLRY is well-positioned to benefit from any positive regulatory developments in the cannabis sector.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly after positive data in prostate cancer trials, while also citing undervaluation. Community talking points center on the company being significantly undervalued with a large short interest, positioning it for a potential squeeze. Some also speculate about potential partnerships and acquisitions in the near future! LOAD!

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending due to increased investor interest, particularly around its partnerships in the defense and aerospace sectors. Community members are discussing the company's growth potential, revenue projections, and potential for a short squeeze given its low float. The stock's overnight movement and potential contracts are also sparking excitement.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to crypto-related sympathy moves amid Bitcoin's volatility, sparking discussions about its low float and potential for a squeeze. The community is weighing the impact of a recent offering and anticipating insights from an upcoming conference. Traders are actively debating its valuation and potential for further upside, while others caution about the risks associated with low-float stocks.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending following its Q3 earnings release, guidance boost, a new buyback authorization, and news of the CEO stepping down in 2026. While some investors are encouraged by the strong results and international growth, others are focused on margin concerns, the CEO transition, and potential market overreaction. The community is actively discussing whether the stock can sustain its gains and reach previous highs, and analyst upgrades.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as community members rally around its meme-driven culture and celebrate its growing presence on Cryptotwits. The community emphasizes its strong, organic growth and relentless focus on memes and community engagement. $PMV holders express bullish sentiment, touting it as the top runner for 2026 and inviting others to join the 'infection'.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is gaining attention, with community members noting its consistent upward momentum and strong buying support. The token, built on Ethereum as an ERC-20, is discussed as a potential leader in the meme coin space, drawing comparisons to Doge and Pepe. Community members highlight a potential narrative around $YEE, with some suggesting a link to Ethereum's resurgence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mural Oncology (NASDAQ:MURA) Insider Sells $10,474.88 in Stock

Mural Oncology PLC (NASDAQ:MURA - Get Free Report) insider Vicki Goodman sold 5,036 shares of Mural Oncology stock in a transaction that occurred on Monday, November 10th. The stock was sold at an...

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive agreement under which a unit of XOMA will acquire Mural for cash.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.muraloncology.com/news-releases/news-release-details/mural-oncology-announces-entry-agreement-be-acquired-xra-5-corp">deal</a>, each Mural Shareholder would receive a cash price of between $2.035 and $2.24 per share. The base cash price represents a premium of approximately 13.1% to Mural’s closing share price of $1.80 on Tuesday. The additional price per share of up to $0.205 will be paid if Mural’s closing net cash exceeds estimates.MURA stock jumped 14% in the premarket session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MURA">Mural</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/XOMA">XOMA</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.Mural's board of directors said that they have determined the acquisition and cash offer by XOMA, a biotechnology royalty aggregator, is in the best interest of all Mural shareholders. The board approved the acquisition and recommended that Mural shareholders vote in favor.The acquisition will be subject to the satisfaction of closing conditions, including approval by Mural shareholders. Excluding additional price per share, the deal values Mural at about $36.2 million.Mural Oncology announced plans to explore strategic alternatives in April after discontinuing all clinical development of Nemvaleukin. The decision followed data from a late-stage trial where Nemvaleukin in combination with Pembrolizumab did not achieve the primary endpoint of a statistically significant improvement in overall survival versus chemotherapy in platinum-resistant ovarian cancer. The company also saw no positive results from a mid-stage study of the drug in mucosal and cutaneous melanoma.MURA stock is down by 44% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mural Oncology To Be Acquired By XOMA Royalty

The Mural board of directors said that they have determined the acquisition and cash offer by XOMA is in the best interest of all its shareholders. 

Equity

Mural Oncology Plc.'s stock (MURA) notched its best session ever on Tuesday, soaring nearly 134%, and extended gains in after-hours trading as the biotech firm said it was exploring strategic alternatives.The cancer drug maker said it would discontinue all clinical development of its lead drug candidate, nemvaleukin alfa, following disappointing data from two Phase 2 trials in melanoma and previously reported Phase 3 results in ovarian cancer.The company also said it had failed to meet the primary endpoint in its ARTISTRY-6 mucosal melanoma study, and preliminary data from a cutaneous melanoma cohort showed insufficient activity to continue.Mural said it plans to explore strategic alternatives, including a potential sale, merger, or other transaction, and has hired Lucid Capital Markets as its financial advisor.&nbsp;It has not received any offers or is in active discussions.&nbsp;As of Dec. 31, 2024, the company held about $144.4 million in cash and equivalents and will cut approximately 90% of its workforce as part of the strategic shift.The news sent message volume involving Mural Oncology on Stocktwits soaring by 62,000%, the highest among healthcare stocks, although sentiment plunged further into 'extremely bearish' territory.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MURA_sentiment_and_message_volume_as_of_April_15_png_97c55d5bff.webp" alt="MURA sentiment and message volume as of April 15.png" width="1318" height="316"><figcaption>MURA sentiment and message volume as of April 15. | source: Stocktwits</figcaption></figure>Several skeptical retail watchers expect the stock to drop below $2 on Wednesday.<stembedurl>https://stocktwits.com/Smehran99/message/611776249</stembedurl><stembedurl>https://stocktwits.com/WMWilson/message/611761469</stembedurl>According to Koyfin, four analysts cover the stock, with two recommending a 'strong buy' and two with a 'hold' rating.Mural Oncology's stock has lost over a quarter of its valuation this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives

The company will cut approximately 90% of its workforce as part of the strategic shift.

Mural Oncology is an independent public company. Mural Oncology would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the company's portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted split interleukin-12 (IL-12) and interleukin-18 (IL-18).

Mural Oncology plc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

MURA
Mural Oncology plc

Feed

News

Sentiment

Fundamentals

Info

Latest MURA News

MURAMural Oncology plc